SG10201601766UA - METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY - Google Patents

METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY

Info

Publication number
SG10201601766UA
SG10201601766UA SG10201601766UA SG10201601766UA SG10201601766UA SG 10201601766U A SG10201601766U A SG 10201601766UA SG 10201601766U A SG10201601766U A SG 10201601766UA SG 10201601766U A SG10201601766U A SG 10201601766UA SG 10201601766U A SG10201601766U A SG 10201601766UA
Authority
SG
Singapore
Prior art keywords
cell
cd1d
enhance
expression
over
Prior art date
Application number
SG10201601766UA
Inventor
Shu Wang
Jieming Zeng
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201601766UA priority Critical patent/SG10201601766UA/en
Publication of SG10201601766UA publication Critical patent/SG10201601766UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10201601766UA 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY SG10201601766UA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201601766UA SG10201601766UA (en) 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2011017373 2011-03-10
SG10201601766UA SG10201601766UA (en) 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY

Publications (1)

Publication Number Publication Date
SG10201601766UA true SG10201601766UA (en) 2016-04-28

Family

ID=55806037

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201601766UA SG10201601766UA (en) 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY
SG2013067517A SG193360A1 (en) 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013067517A SG193360A1 (en) 2011-03-10 2012-03-09 METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY

Country Status (2)

Country Link
SG (2) SG10201601766UA (en)
WO (1) WO2012121678A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU0301358D0 (en) * 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists

Also Published As

Publication number Publication date
SG193360A1 (en) 2013-10-30
WO2012121678A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
IL264271A (en) Methods of generating natural killer cells
EP2761291A4 (en) System and method to separate cells and/or particles
SG10201610915XA (en) Methods and compositions for natural killer cells
EP2739587A4 (en) Cell capture system and method of use
ZA201306573B (en) Transcutaneous stimulation method and system
HK1185918A1 (en) Dipeptides to enhance yield and viability from cell cultures
EP2691980A4 (en) Thin silicon solar cell and method of manufacture
EP2891712A4 (en) Method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro
EP2534644A4 (en) Method and system for display of objects in 3d
HK1201419A1 (en) Natural sweetener and method of making
EP2606123A4 (en) Methods of generating oligodendrocytes and cell populations comprising same
HK1205591A1 (en) Protective coating-encapsulated photovoltaic modules and methods of making same
MX349544B (en) Maesa japonica extracts and methods of use.
EP2714709A4 (en) Cell and gene based methods to improve cardiac function
ZA201207064B (en) Device and method to determine shape of streamer
GB2495601B (en) Systems and methods for producing directed seismic waves in water
HK1254929A1 (en) Enhanced natural sweetener and method of making
EP2878666A4 (en) Industrial preparation of natural killer cells (nks) and injection using human allogeneic karyocytes
SG11201400199XA (en) Engineered sequences to facilitate expression of antigens in neisseria and methods of use
ZA201203957B (en) Float-sink method and apparatus to determine benefication prospects of minerals
SI2913394T1 (en) Co-differentiation and activation of monocytes from allogeneic donors to provide pro-inflammatory dendritic cells
EP2699672A4 (en) Method to produce virus in cultured cells
SG11201405535PA (en) Apparatus and method to reduce particles in advance anneal process
HK1211729A1 (en) Method and apparatus to detect artificial edges in images
SG10201601766UA (en) METHOD OF USING CD1d OVER-EXPRESSION IN HUMAN DENDRITIC CELLS TO ENHANCE CD8+ T CELL-BASED AND INVARIANT NATURAL KILLER T CELL- BASED ANTITUMOR IMMUNITY